Alzheimer’s: ‘Magic mushrooms’ temporarily reversed symptoms in 80-year-old Brazilian patient

—

in

An 80-year-old woman with advanced Alzheimer’s disease—who had lost the ability to communicate and move independently—experienced significant, temporary improvement in her symptoms after receiving psilocybin, a psychoactive compound found in so-called ‘magic mushrooms’.

What is psilocybin?

Psilocybin is a naturally occurring psychedelic substance produced primarily by fungi in the Psilocybe genus. Though classified as an illegal drug in most countries, recent research has explored its potential therapeutic effects on brain function. Animal studies suggest psilocybin can transiently alter brain network dynamics, activating mechanisms linked to neuroplasticity—the brain’s ability to reorganize itself following injury, disease, or new experiences.

However, researchers note in the journal Frontiers in Neuroscience that comparable evidence in humans remains lacking.

A severe, progressive case

The patient had suffered from worsening Alzheimer’s for a decade. In the last five years, her condition deteriorated markedly: she was largely nonverbal, dependent on family for mobility, and experienced chronic urinary incontinence and dysphagia (difficulty swallowing food and liquids). She showed minimal spontaneous communication and no observable emotional responsiveness.

High-dose treatment under medical supervision

With consent from her family, doctors in Brazil administered a high dose of psilocybin—nearly triple the amount typically used recreationally. She remained under continuous medical monitoring throughout.

What happened next?

Initially, she developed hyperthermia, intense sweating, and profound drowsiness, leading to an extended sleep-like state lasting nearly 19 hours. Upon waking, she suddenly began speaking about herself—and continued for several hours.

Within days, she walked unassisted and dressed herself independently. Over the following weeks, her urinary incontinence resolved—even overnight—and her mobility and interpersonal communication improved markedly.

So striking were the results that, one month later, clinicians administered a second, lower—but still high—dose. This time, she maintained verbal fluency, began using facial expressions and humor with caregivers, displayed emotional closeness, and further improved her ability to walk without assistance.

Important caveats

Scientists emphasize this does not represent a cure for Alzheimer’s. They describe the outcome as a ‘transient functional improvement’—noting they have not yet followed the patient long enough to determine how long the effects may last. Moreover, this is a single-case report. There is no guarantee similar responses would occur in other patients, nor is psilocybin currently approved or recommended for Alzheimer’s treatment outside of controlled research settings.